Benfotiamine

Alternative Medicine Review

Volumn 11, Issue 3, 2006, Pages 238-242

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BENFOTIAMINE; MILGAMMA N; THIAMINE; VITAMIN B COMPLEX; BENPHOTHIAMINE; DRUG DERIVATIVE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALCOHOLISM; BIOCHEMISTRY; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; FOOD DRUG INTERACTION; HUMAN; KIDNEY FAILURE; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL VASCULAR DISEASE; REVIEW; THIAMINE DEFICIENCY; ARTICLE; CHRONIC KIDNEY FAILURE;

ALCOHOLIC NEUROPATHY; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; HUMANS; RENAL INSUFFICIENCY, CHRONIC; THIAMINE;

EID: 33749579055     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Greb A, Bitsch R. Comparative bioavailability of various thiamine derivatives after oral administration. Int J Clin Pharmacol Ther 1998;36:216-221.
2. Ziems M, Netzel M, Bitsch I. Biokinetic parameters and metabolism of S-benzoylthiamine-O-monophosphate. BioFactors 2000;11:109-110.
3. Bitsch R, Wolf M, Moller J, et al. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivative. Ann Nutr Metab 1991;35:292-296.
4. Loew D. Pharmacokinetics of thiamine derivatives especially of benfotiamine. Int J Clin Pharmcol Ther 1996;34:47-50.
5. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9:294-299.
6. Berrone E, Beltramo E, Solimine C, et al. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006;281:9307-9313.
7. Pomero F, Molinar Min A, La Selva M, et al. Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose. Acta Diabetol 2001;38:135-138.
8. Beltramo E, Berrone E, Buttiglieri S, Porta M. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev 2004;20:330-336.
9. Gadau S, Emanueli C, Van Linthout S, et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/AKT mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 2006;49:405-420.
10. Mestyan I, Jobst K, Hazafi K, Green A. Erythrocyte transketolase activity in patients with chronic renal disease. Acta Med Hung 1986;43:315-319.
11. Babaei-Jadidi R, Karachalias N, Ahmed N, et al. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003;52:2110-2120.
12. Woelk H, Lehrl S, Bitsch R, Kopeke W. Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAPI Study). Alcohol Alcohol 1998;33:631-638.
13. Thomson AD. Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndrome. Alcohol Alcohol Suppl 2000;35:2-7.
14. Abbas ZG, Swai AB. Evaluation of the efficacy of thiamine and pyridoxine in the treatment of symptomatic diabetic peripheral neuropathy. East Afr Med J 1997;74:803-808.
15. Koike H, Misu K, Hattori N, et al. Postgastrectomy polyneuropathy with thiamine deficiency. J Neurol Neurosurg Psychiatry 2001;71:357-362.
16. Malinowski SS. Nutritional and metabolic complications of bariatric surgery. Am J Med Sci 2006;331:219-225.
17. Haupt E, Ledermann H, Kopeke W. Benfotiamine in the treatment of diabetic polyneuropathy - a three-week randomized, controlled pilot study (BEDIP Study). Int J Clin Pharmacol Ther 2005;43:71-77.
18. Simeonov S, Pavlova M, Mitkov M, et al. Therapeutic efficacy of "Milgamma" in patients with painful diabetic neuropathy. Folia Med (Plovdiv) 1997;39:5-10.
19. Winkler G, Pal B, Nagybeganyi E, et al. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung 1999;49:220-224.
20. Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 1996;104:311-316.
21. No authors listed. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
22. Wu S, Ren J. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosci Lett 2006;394:158-162.
23. Ceylan-Isik AF, Wu S, Li Q, et al. High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. J Appl Physiol 2006;100:150-156.
24. Lange K, Lonergan ET, Semar M, Sterzel RB. Transketolase inhibition as a mechanism in uremic neuropathy. Trans Assoc Am Physicians 1971;84:172-181.
25. Frank T, Bitsch R, Maiwald J, Stein G. High thiamine diphosphate concentrations in erythrocytes can be achieved in dialysis patients by oral administration of benfotiamine. Eur J Clin Pharmacol 2000;56:251-257.